These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 9041189)
1. Electromotive delivery of mitomycin C into human bladder wall. Di Stasi SM; Vespasiani G; Giannantoni A; Massoud R; Dolci S; Micali F Cancer Res; 1997 Mar; 57(5):875-80. PubMed ID: 9041189 [TBL] [Abstract][Full Text] [Related]
2. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Di Stasi SM; Giannantoni A; Massoud R; Dolci S; Navarra P; Vespasiani G; Stephen RL Cancer Res; 1999 Oct; 59(19):4912-8. PubMed ID: 10519404 [TBL] [Abstract][Full Text] [Related]
3. Electromotive administration of oxybutynin into the human bladder wall. Di Stasi SM; Giannantoni A; Massoud R; Cortese C; Vespasiani G; Micali F J Urol; 1997 Jul; 158(1):228-33. PubMed ID: 9186365 [TBL] [Abstract][Full Text] [Related]
4. Penetration of mitomycin C in human bladder. Wientjes MG; Badalament RA; Wang RC; Hassan F; Au JL Cancer Res; 1993 Jul; 53(14):3314-20. PubMed ID: 8324743 [TBL] [Abstract][Full Text] [Related]
5. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Dalton JT; Wientjes MG; Badalament RA; Drago JR; Au JL Cancer Res; 1991 Oct; 51(19):5144-52. PubMed ID: 1913640 [TBL] [Abstract][Full Text] [Related]
7. Bladder wall penetration of intravesical mitomycin C in dogs. Wientjes MG; Dalton JT; Badalament RA; Drago JR; Au JL Cancer Res; 1991 Aug; 51(16):4347-54. PubMed ID: 1907883 [TBL] [Abstract][Full Text] [Related]
8. Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer. Di Stasi SM; Riedl C World J Urol; 2009 Jun; 27(3):325-30. PubMed ID: 19234707 [TBL] [Abstract][Full Text] [Related]
9. Electromotive drug administration to the urinary bladder: an animal model and preliminary results. Gürpinar T; Truong LD; Wong HY; Griffith DP J Urol; 1996 Oct; 156(4):1496-501. PubMed ID: 8808916 [TBL] [Abstract][Full Text] [Related]
10. Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy). Pierconti F; Straccia P; Emilio S; Bassi PF; De Pascalis I; Marques RC; Volavsek M; Larocca LM; Lopez-Beltran A Pathol Res Pract; 2017 Sep; 213(9):1078-1081. PubMed ID: 28843746 [TBL] [Abstract][Full Text] [Related]
11. [Intravesical Electromotive Drug Administration®(EMDA)with Mitomycin-C for non-muscle invasive bladder cancer]. Di Stasi SM; Dutto L; Verri C Urologia; 2008; 75(4):214-20. PubMed ID: 21086335 [TBL] [Abstract][Full Text] [Related]
12. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Brausi M; Campo B; Pizzocaro G; Rigatti P; Parma A; Mazza G; Vicini A; Stephen RL Urology; 1998 Mar; 51(3):506-9. PubMed ID: 9510365 [TBL] [Abstract][Full Text] [Related]
13. [Intravesical therapy with mitomycin through electromotive drug administration]. Verri C; Liberati E; Celestino F; De Carlo F; Torelli F; Di Stasi SM Urologia; 2013; 80(2):105-11. PubMed ID: 23852927 [TBL] [Abstract][Full Text] [Related]
14. Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Gao X; Au JL; Badalament RA; Wientjes MG Clin Cancer Res; 1998 Jan; 4(1):139-43. PubMed ID: 9516962 [TBL] [Abstract][Full Text] [Related]
15. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080 [TBL] [Abstract][Full Text] [Related]
16. Concentrations of mitomycin C in rabbit corneal tissue and aqueous humor after topical administration. Song JS; Kim JH; Yang M; Sul D; Kim HM Cornea; 2006 Dec; 25(10 Suppl 1):S20-3. PubMed ID: 17001187 [TBL] [Abstract][Full Text] [Related]
17. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. Bilensoy E; Sarisozen C; Esendağli G; Doğan AL; Aktaş Y; Sen M; Mungan NA Int J Pharm; 2009 Apr; 371(1-2):170-6. PubMed ID: 19135514 [TBL] [Abstract][Full Text] [Related]
18. Intrascleral concentration vs depth profile of mitomycin-C after episcleral application: impact of applied concentration and volume of mitomycin-C solution. Vass C; Georgopoulos M; el Menyawi I; Radda S; Nimmerrichter P Exp Eye Res; 2000 May; 70(5):571-5. PubMed ID: 10870515 [TBL] [Abstract][Full Text] [Related]
19. In vitro diffusion of mitomycin-C into human sclera after episcleral application: impact of diffusion time. Georgopoulos M; Vass C; El Menyawi I; Radda S; Graninger W; Menapace R Exp Eye Res; 2000 Nov; 71(5):453-7. PubMed ID: 11040080 [TBL] [Abstract][Full Text] [Related]
20. Cell proliferation and DNA content in rat urothelial lesions after repeat intravesical instillations of mitomycin C and bacillus Calmette-Guérin. Oliveira P; Palmeira C; Colaço A; De la Cruz P LF; Lopes C Urol Int; 2008; 80(1):90-7. PubMed ID: 18204241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]